Alexander, Tobias <br/><br/>
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.  [electronic resource] 

 -  European journal of immunology  09 2018 
 - 1573-1579 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-4141 
<br/><br/><label>Standard No.: </label>10.1002/eji.201847492  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Autoantibodies--blood<br/>Bortezomib--therapeutic use<br/>Complement System Proteins--metabolism<br/>Humans<br/>Immunoglobulins--blood<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Lymphocyte Count<br/>Plasma Cells--cytology<br/>Precursor Cells, B-Lymphoid--cytology<br/>Precursor Cells, T-Lymphoid--cytology<br/>Proteasome Endopeptidase Complex--drug effects<br/>Proteasome Inhibitors--therapeutic use